R&D is
the heart of our mission to develop global medicines for incurable diseases.
Project code | Indication | Discovery | Preclinical | Phase1 | Phase2 | Phase3 | Partners | |
---|---|---|---|---|---|---|---|---|
Immunology | HL036 (tanfanercept) | Dry eye disease (DED) |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]() (China) |
HL161 (batoclimab) | Myasthenia gravis (MG) |
![]() |
![]() |
![]() |
![]() |
![]() ![]() (US/EU) (China) |
||
Thyroid eye disease (TED) |
![]() |
![]() |
![]() |
![]() |
![]() ![]() (US/EU) (China) |
|||
Warm autoimmune hemolytic anemia (WAIHA) |
![]() |
![]() |
![]() |
![]() |
![]() (US/EU) |
|||
Neuromyelitis optica (NMO) |
![]() |
![]() |
![]() |
![]() |
![]() (China) |
|||
Immune thrombocytopenia (ITP) |
![]() |
![]() |
![]() |
![]() |
![]() (China) |
|||
HL189 (tanfanercept) | Non-Infectious uveitis(NIU) |
![]() |
![]() |
|||||
Oncology | HL186/HL187 | Immuno-oncology |
![]() |
![]() |